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The WHO 2014 Global tuberculosis report—further to go
In May 2014, the World Health Assembly oﬃ  cially 
approved the Draft Global Strategy and Targets for 
Tuberculosis Prevention, Care and Control after 
2015.1 The target of the strategy is the elimination of 
tuberculosis as a public health threat by 2035. This 
target is ambitious, but the commitment to the end 
of tuberculosis is laudable. The recently published 
19th WHO global tuberculosis report 2014,2 provides 
an opportunity to think once again on the global 
tuberculosis strategy, and to assess just how much 
further eﬀ ort is needed before global tuberculosis 
control can be achieved.
Previously,3 we declared that the 1·3 million deaths 
per year from tuberculosis reported in the 2013 WHO 
global tuberculosis report was unacceptable in the 
21st century. The latest 2014 WHO global tuberculosis 
report has revised its estimates of new tuberculosis 
cases worldwide from previous years, and now shows 
that almost half a million more cases of tuberculosis 
occurred worldwide than in their 2013 estimate.4 Of an 
estimated 9 million people who developed tuberculosis 
in 2013, 1·5 million people died (deaths up from 
1·3 million estimated in 2012). 
The 2014 WHO report also states that the problem 
of drug-resistant tuberculosis is worsening, with an 
estimated 480 000 new cases of multidrug-resistant 
(MDR) tuberculosis in 2013. This number too might be 
an underestimate, since estimates for the true burden 
of drug-resistant tuberculosis across sub-Saharan Africa, 
Asia, and eastern Europe are impaired by the fact that 
drug-resistance testing and treatment services are 
generally unavailable at most health-care facilities.5,6 
Perhaps even more concerning was that, of the nearly 
half a million estimated cases of MDR tuberculosis 
worldwide, only 136 000 cases were oﬃ  cially diagnosed. 
The outlook for these patients is bleak, with treatment 
completion rates remaining at 48% and a widening 
gap between people who are diagnosed and those who 
receive treatment.  Furthermore, 9% of people with MDR 
tuberculosis are estimated to have extensively drug-
resistant (XDR) tuberculosis—ie, nearly 50 000 people 
worldwide have a form of the disease that, at present, 
cannot be treated.
The increased revised estimates in the 2014 report 
arise from a series of studies in ﬁ ve high-burden 
countries: Gambia, Laos, Nigeria, Pakistan, and Rwanda.
One of these countries, Nigeria, was reported to have 
a tuberculosis diagnosis rate of about 50%—ie, only 
half of all people with tuberculosis were notiﬁ ed that 
they had the disease.2 After the prevalence study, it was 
estimated that just 16% of all patients with tuberculosis 
were notiﬁ ed by the national treatment programme. 
Results from a similar study in Indonesia2 showed that 
prevalence had been substantially underestimated and 
the number of cases could be nearly one million more 
than were previously estimated. The report states that 
the rate of progress against the disease has remained 
largely unchanged. The number of new cases has 
decreased by roughly 1·5% each year between 2000 and 
2013. At these present rates of progress, the target of 
elimination by 2035 seems remote. 
So what can be done by the global community to 
accelerate progress to achieve global targets? First, 
many cases of tuberculosis are clearly not oﬃ  cially 
diagnosed or treated. The so-called missing 3 million 
continue to be a major driver of the epidemic. This 
challenge was the theme of World Tuberculosis Day 
2014.7 People with active tuberculosis who are not 
treated can transmit the disease to others, while 
people who are treated unoﬃ  cially, outside national 
tuberculosis programmes, are at increased risk of 
developing drug-resistant strains of the disease. As 
the revised data and other studies suggest,8,9 the more 
tuberculosis is looked for, the more is found. Therefore, 
approaches are needed that look for tuberculosis more 
thoroughly, and diagnose more people as soon as 
possible, allowing them to receive the appropriate high-
quality treatment. Fully funded  projects like TB REACH, 
which has a proven record of piloting innovative ways 
to diagnose and treat great numbers of people, would 
be a good ﬁ rst step.
If the gap between those who are oﬃ  cially diagnosed 
and those who are ill can be closed, transmission 
reduction can begin, and progress against the disease 
can be accelerated. The ﬁ ght against HIV has adopted a 
powerful message of treatment as prevention—this is 
even more appropriate in the ﬁ ght against tuberculosis. 
This eﬀ ort must be led by the countries with the 
heaviest tuberculosis burdens; donor countries can 
provide ﬁ nancial and technical assistance, strengthen 
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health systems, and help to identify innovative methods 
to reach patients, but these eﬀ orts must be locally led.
If the search for and treatment of patients must be 
done at the local level, what more can donor countries 
do to help defeat the disease? The answer is simple: more 
resources are needed for proactive screening, and new 
ways to diagnose, prevent, and treat tuberculosis should 
be identiﬁ ed. A report by the Treatment Action Group,10 
released on the same day as the Global tuberculosis 
report 2014,2 shows how little is invested in tuberculosis 
research and development, compared with what is 
needed. The 2014 Report on Tuberculosis Research 
Funding Trends10 revealed that total global investment 
in tuberculosis research and development was about 
US$675 million. Although this amount might seem 
substantial, it is barely a third of the estimated $2 billion 
needed to develop new drugs, vaccines, and diagnostics.
In October, 2014, the All Party Parliamentary Group on 
Global Tuberculosis published a report11 investigating the 
failure to develop much-needed new drugs for neglected 
diseases—including tuberculosis—that aﬀ ect millions of 
people but represent a relatively small ﬁ nancial market. 
The report made clear that the commercial market had 
failed with respect to these products. Treatment Action 
Group’s report10 estimates that, in 2013, spending on 
tuberculosis by pharmaceutical companies was just 
$99 million. This total is the lowest since Treatment 
Action Group started reporting research spending in 
2005.
Where markets fail, governments must intervene, 
and the UK is a global leader in this ﬁ eld. The UK Prime 
Minister launched a commission12 into the failure of 
markets to develop new antibiotics, and much of the 
commission’s work will be equally relevant to failures 
to develop new tuberculosis drugs. The Department 
for International Development13 has committed 
£150 million over 5 years for product development 
partnerships—non-proﬁ t organisations that seek to 
develop treatments for diseases that do not attract 
attention from pharmaceutical companies. Nonetheless, 
these investments are small compared with both the 
resources needed for, and the potential rewards of, for 
example, a new tuberculosis or HIV vaccine. The future 
challenge is to convince other countries to invest more 
in research and development for global health.
Irrespective of development of new drugs, 
diagnostics, and an eﬀ ective vaccine, which could 
transform the ﬁ ght against tuberculosis, much can 
be done with the methods available at present. We 
reiterate3 that the means, knowledge, and expertise 
to achieve global tuberculosis control exist, and the 
time has come for urgent, swift, and visionary action 
to enable stepping up of the eﬀ orts in tuberculosis 
control and to drive down tuberculosis incidence as 
soon as possible. Increased ﬁ nancial investment into 
universal access to high-quality care for all people with 
tuberculosis, and reduction of human suﬀ ering and 
socioeconomic burden associated with tuberculosis 
should be prioritised by all governments and donors. 
Tuberculosis is curable and to reach the missing 3 
million (or more) and treat them will be a crucial 
step towards the ultimate goal of the elimination of 
tuberculosis.
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